{"classes":[{"categories":[{"measurements":[{"comment":"Due to early termination and low number of participants with post-baseline assessment, median and upper limit of 95% CI was not reached.","groupId":"OG000","lowerLimit":"6.70","upperLimit":"NA","value":"NA"},{"comment":"Due to early termination and low number of participants with post-baseline assessment, upper limit of 95% CI was not reached.","groupId":"OG001","lowerLimit":"4.99","upperLimit":"NA","value":"9.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"description":"Duration of clinical benefit was defined as the time from first documented evidence of confirmed MR or better until the earliest date of a confirmed PD per IMWG, or death among participants who achieve a confirmed MR or better. MR: ≥25% but ≤49% reduction of serum M-protein and reduction in 24-hour urine M-protein by 50% to 89%. Per IMWG criteria, PD: serum M-component increase ≥0.5 g/dl or urine M-component increase ≥ 200 mg/24-hour/ difference between involved and uninvolved FLC levels increase \\>10 mg/dl or bone marrow plasma cell ≥10%/ development of new/ increase in size of existing bone lesions or soft tissue plasmacytoma or development of hypercalcemia.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.","id":"OG000","title":"Part 3 (Dose Extension): Modakafusp Alfa 120 mg"},{"description":"Participants received modakafusp alfa 240 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.","id":"OG001","title":"Part 3 (Dose Extension): Modakafusp Alfa 240 mg"}],"paramType":"MEDIAN","populationDescription":"The FAS included all participants who received at least 1 dose, even an incomplete dose, of modakafusp alfa, in the Part 3 extension cohorts. Overall number of participants analyzed is the number of participants with events. Participants with no post baseline response assessment were censored.","reportingStatus":"POSTED","timeFrame":"Up to 20.5 months in Part 3","title":"Part 3: Duration of Clinical Benefit","type":"SECONDARY","unitOfMeasure":"months"}